Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
dc.contributor.author | Rishi, Pukhraj | en_US |
dc.contributor.author | Rishi, Ekta | en_US |
dc.contributor.author | Shroff, Daraius | en_US |
dc.date.accessioned | 2009-05-23 | en_US |
dc.date.accessioned | 2009-05-29T08:27:11Z | |
dc.date.available | 2009-05-23 | en_US |
dc.date.available | 2009-05-29T08:27:11Z | |
dc.date.issued | 2009-05-23 | en_US |
dc.description.affiliation | Shri Bhagwan Mahavir Vitreoretinal Services, Medical and Vision Research Foundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu, India. docrishi@yahoo.co.in. | en_US |
dc.identifier.citation | Rishi P, Rishi E, Shroff D. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia. Indian Journal of Ophthalmology. 2009 May-Jun; 57(3): 241-2 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/70491 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.ijo.in | en_US |
dc.source.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683442/ | en_US |
dc.subject.mesh | Angiogenesis Inhibitors --therapeutic use | |
dc.subject.mesh | Antibodies, Monoclonal --therapeutic use | |
dc.subject.mesh | Antibodies, Monoclonal, Humanized | |
dc.subject.mesh | Combined Modality Therapy | |
dc.subject.mesh | Fluorescein Angiography | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Injections | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Photochemotherapy | |
dc.subject.mesh | Retinal Diseases --diagnosis | |
dc.subject.mesh | Retinal Diseases --drug therapy | |
dc.subject.mesh | Retinal Diseases --physiopathology | |
dc.subject.mesh | Retinal Neovascularization --diagnosis | |
dc.subject.mesh | Retinal Neovascularization --drug therapy | |
dc.subject.mesh | Retinal Neovascularization --physiopathology | |
dc.subject.mesh | Retinal Vessels --pathology | |
dc.subject.mesh | Telangiectasis --diagnosis | |
dc.subject.mesh | Telangiectasis --drug therapy | |
dc.subject.mesh | Tomography, Optical Coherence | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Vascular Endothelial Growth Factor A --antagonists & inhibitors | |
dc.subject.mesh | Visual Acuity | |
dc.subject.mesh | Vitreous Body | |
dc.subject.mesh | Vascular Endothelial Growth Factor A --antagonists & inhibitors | |
dc.subject.mesh | Vitreous Body | |
dc.title | Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia. | en_US |
dc.type | Letter | en_US |
Files
License bundle
1 - 1 of 1